Financial Conflict of Interest for National Institutes of Health (NIH) and Other Applicable Research Funding Sources Reporting and Assessment Procedure

### Overview

In addition to compliance with the University’s Conflict Policy – Conflict of Interest and Commitment and Institutional Conflict and the other accompanying procedures, all investigators, who are applying for and/or receiving NIH funding or who are participating in a NIH-funded research project, whether directly or through a subcontract, must comply with this procedure.

### Purpose

- To clarify reporting requirements regarding reporting of **significant financial interests (SFI)** by University personnel;
- To outline the process by which a **designated official** confirms whether the SFI is connected to an investigator’s **institutional responsibilities** and assesses whether it is a **financial conflict of interest (FCOI)** for a NIH-funded project;
- To outline the responsibilities of the designated official and the University in managing and reporting FCOIs to NIH; and
- To promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct, and reporting of research funded under NIH grants or cooperative agreements will be free from bias resulting from investigator FCOIs

in order to comply with PHS regulations (**US regulations**: 42 CFR Part 50 Subpart F and 45 CFR Part 94).

### PROCEDURE

#### Summary

1. **REPORTING BY INVESTIGATORS**
2. ASSESSMENT AND RECORD-KEEPING BY DESIGNATED OFFICIAL

3. MANAGEMENT AND REPORTING OF FCOI

4. OTHER UNIVERSITY AND INVESTIGATOR RESPONSIBILITIES: TRAINING, SUBCONTRACTING AND PUBLIC ACCESSIBILITY OF INFORMATION

5. NON-COMPLIANCE CONSTITUTES MISCONDUCT

1. REPORTING BY INVESTIGATORS

1.1. Who must disclose:

All investigators who are:

- applying for and/or receiving NIH funding, or
- who are working on a NIH-funded research project

whether directly or through subcontract, must disclose, in writing to the designated official at the University, all SFIs (and those of the investigator's spouse and dependent children) at the following times:

a. Initial disclosure:

i. initial disclosure must be made at least 30 days before the time of application for NIH-funded research;

ii. the initial disclosure must include all SFIs in the 12 months preceding the disclosure.

b. Ongoing disclosure:

i. within 30 days of discovering or acquiring (including but not limited to a purchase, marriage, inheritance, etc.) a new SFI, and

ii. on an annual basis during the term of the NIH-funded research, disclosure of:

- all SFIs received in the 12 months preceding the disclosure that were not previously reported; and
- updated information regarding any previously disclosed SFI.

c. New to the University:

All investigators who are new to the University and are applying for and/or receiving NIH funding or who are participating in a NIH-funded research project must make the initial disclosure and ongoing disclosures as noted above.

1.2 Steps to Disclose Significant Financial Interests to the University

To disclose Significant Financial Interests to the University:

a. the investigator, his/her spouse and his/her dependent children must complete the appropriate Disclosure and Consent Form for Significant Financial Interests attached to this Procedure and return it to the designated official.

b. the designated official will determine whether the third party entity(ies) or individual(s) named in the significant financial interest(s) disclosed by an investigator (or spouse and/or dependent child[ren]), should be informed of the disclosure and the fact that the disclosed information may be made available to the NIH or, in the case of a financial conflict of interest, to the public. The designated official will provide the informed third party entity or individual with the opportunity to indicate any concern with such access to the SFI information and may obtain consent using the Informed Consent Form from Third Party for Disclosure of Personal Information attached to this Procedure.

[return to Summary]

2. ASSESSMENT AND RECORD-KEEPING BY DESIGNATED OFFICIAL

a. The designated official must review all disclosures of SFIs from investigators, including subrecipient investigators, within the timeframes noted below in 2b, and determine whether:

i. the disclosures relate to NIH funding; and
- an investigator’s SFI is related to NIH research when the designated official reasonably determines that the SFI:
  - could be affected by the NIH-funded research; or
  - is an entity whose financial interest could be affected by the research.

The designated official may involve the investigator in the designated official’s determination of whether a SFI is related to the NIH-funded research.

  ii. whether each SFI is a FCOI.

  - a FCOI exists when the University, through its designated official, reasonably determines that the SFI could directly and significantly affect the design, conduct, or reporting of the NIH-funded research.

b. The review and determination noted in 2a above must be conducted by the designated official at the following times:

  i. prior to the University’s expenditure of any funds under a NIH-funded research project;

  ii. within sixty (60) days whenever, in the course of an ongoing NIH-funded project, an investigator or subrecipient investigator who is new to participating in the project discloses a SFI or an existing investigator or subrecipient investigator discloses a new SFI to the University; and

  iii. within sixty (60) days whenever the University identifies a SFI that:

  - was not disclosed in a timely manner by an investigator or subrecipient investigator; or

  - for whatever reason, was not previously reviewed by the University during an ongoing NIH-funded research project.

c. Record-keeping - The designated official, on behalf of the University, must maintain records relating to all investigator disclosures of SFIs and the University's review of, and response to, such disclosures (whether or not a disclosure resulted in the University’s determination of a FCOI) and all actions under the University’s policy or retrospective review related to the SFI and/or FCOI, if applicable, for at least three (3) years from the date the final expenditures report is submitted to NIH, the date of final payment or, where applicable, for other time periods specified.

d. NIH may inquire at any time (before, during, after award) into any investigator disclosure of financial interests and the University’s review of, and response to, such disclosure, whether or not the disclosure resulted in the University’s determination of a FCOI. This includes situations in which an investigator moves from one university to another.

e. The University is required to submit to NIH, or permit NIH on site to review, all records pertinent to compliance with this Procedure.

[return to Summary]

3. MANAGEMENT AND REPORTING OF FCOI

a. If the designated official determines through his or her review pursuant to 2a above that there is a FCOI, the designated official must prepare a FCOI management plan to manage the FCOI. Key elements of the management plan include:

  - role and principal duties of the conflicted investigator in the research project;
  - conditions of the management plan;
  - how the management plan is designed to safeguard objectivity in the research project;
  - confirmation of the investigator’s agreement to the management plan;
  - how the management plan will be monitored to ensure investigator compliance; and
  - other information as needed.

Examples of conditions or restrictions that might be imposed to manage a FCOI:

  - public disclosure of FCOI (e.g., when presenting or publishing research);
  - for research projects involving humans, disclosure of FCOI directly to the participants;
  - appointment of an independent monitor capable of taking measures to protect the design, conduct, and reporting of the research against bias resulting from a FCOI;
U of A Policies and Procedures On-Line (UAPPOL)

- modification of the research plan;
- change of personnel or personnel responsibilities, or disqualification of personnel from participation in all or a portion of the research;
- reduction or elimination of the financial interest (e.g., sale of an equity interest), or
- severance of relationships that create financial conflicts of interest.

b. The investigator is required to comply with the management plan prescribed by the designated official.

c. On behalf of the University, the designated official must monitor compliance with the management plan on an ongoing basis until the completion of the project.

d. Reporting requirements to NIH
The University, through its designated official, must provide initial and ongoing FCOI reports to NIH as applicable:

i. after the award is granted but prior to the University’s expenditure of any funds under a NIH-funded research project;

ii. annually at the same time as the annual progress report is due:
For any FCOI previously reported by the University, the report must address the status of the FCOI and any changes to the management plan for the duration of the NIH-funded research project. The annual FCOI report must specify whether the financial conflict is still being managed or explain why the FCOI no longer exists.

iii. in the time and manner specified by NIH for any other FCOI reports for the duration of project period (including extensions with or without funds).

iv. subrecipients: The University must provide FCOI reports to NIH regarding all FCOIs of all subrecipient investigators prior to the expenditure of funds and within 60 days of any subsequently identified FCOI.

FCOI reports by the University must include sufficient information to enable NIH to understand the nature and extent of the financial conflict, and to assess the appropriateness of the University’s management plan. Each FCOI report prepared by the designated official on behalf of the University must contain:

- grant number;
- project director/principal investigator or contact project director/principal investigator if a multiple project director/principal investigator model is used;
- name of investigator with the FCOI;
- name of the entity with which the investigator has a FCOI;
- nature of FCOI (e.g., equity, consulting fees, travel reimbursement, honoraria);
- value of the financial interest per year:
  - $0-$4,999;
  - $5,000-$9,999;
  - $10,000-$19,999;
  - amounts between $20,000-$100,000 by increments of $20,000;
  - amounts above $100,000 by increments of $50,000; or
  - a statement that a value cannot be readily determined
- a description of how the financial interest relates to NIH-funded research and the basis for the University’s determination that the financial interest conflicts with such research; and
- key elements of the University’s management plan.

[return to Summary]

4. OTHER UNIVERSITY AND INVESTIGATOR RESPONSIBILITIES: TRAINING, SUBCONTRACTING AND PUBLIC ACCESSIBILITY OF INFORMATION

a. Training:
The University must provide the following mandatory training, as prescribed in the NIH regulations, to its investigators:

i. inform each investigator of the University's policy on FCOIs
ii. inform each investigator of the investigator’s responsibilities regarding the disclosure of SFIs and the NIH regulations

iii. require each investigator to complete training regarding the University’s policy on FCOIs and the investigator’s responsibilities:
   - prior to engaging in NIH-funded research,
   - at least every four years, and
   - immediately when any of the following circumstances apply:
     - the University revises its financial conflict of interest policies
     - an investigator is new to the University
     - the University finds that an investigator is not in compliance with the University’s financial conflict of interest policy or management plan.

   The investigator must undertake such training from the University.

b. Subcontracting

If the University carries out the NIH-funded research through a subrecipient, the University must take reasonable steps to ensure that any subrecipient investigator complies with this procedure:

i. incorporate as part of written agreement with subrecipient, terms that establish whether this procedure or the subrecipient’s policy will apply to the subrecipient’s investigators.

ii. if the subrecipient’s investigators must comply with the subrecipient’s financial conflicts of interest policy, the University shall obtain from the subrecipient as part of the written agreement referenced above a certification that its policy complies with the NIH regulations, specifically 42 CFR Part 50 Subpart F or 45 CFR Part 94. The agreement shall also specify the time periods for the subrecipient to report all identified financial conflicts of interest to the University. Such time periods shall be sufficient to enable the University to provide timely FCOI reports, as necessary, to the NIH as required by this procedure.

iii. if the subrecipient’s investigators must comply with this procedure, the University must obtain a written agreement specifying time periods for the subrecipient to submit all investigator disclosures of significant financial interests to the University. Such time periods shall be sufficient to enable the University to comply in a timely fashion with its review, management and reporting obligations under this procedure.

c. Public Accessibility of Information

i. the University shall maintain an up-to-date, written, enforced policy (and associated procedures) on financial conflicts of interest, that complies with NIH regulations and make such policy available via a publicly accessible website.

ii. after an award has been granted, but prior to the University’s expenditure of any funds under a NIH-funded research project, the University shall make available, via a publicly accessible website or in writing within five (5) business days of any request, the information listed in 4.c.iii. concerning any SFI that meets the following criteria:
   - SFI was disclosed and is still held by the investigator who has been identified by the University as senior/key personnel for the NIH-funded research project in the grant application, contract proposal, contract, progress report, or other required report submitted to the NIH;
   - the University determines that the SFI is related to the NIH-funded research; and
   - the University determines that the SFI is a FCOI.

iii. the University must post on the publicly accessible website or make available in response to written requests the following minimum information:
   - investigator’s name,
   - investigator’s position with respect to the research project,
   - nature of the SFI,
   - approximate dollar value of the SFI:
     - $0-$4,999;
     - $5,000-$9,999;
     - $10,000-$19,999;
- amounts between $20,000-$100,000 by increments of $20,000;
- amounts above $100,000 by increments of $50,000 or
- a statement that a value cannot be readily determined;
- the entity with which the investigator has a FCOI, to enhance transparency and accountability.

iv. the University shall update the above-noted information within 60 days when there are changes to the information and, at a minimum, shall update the above-noted information annually.

v. the above-noted information, as updated, shall remain available for responses to written requests or for posting via the University’s publicly accessible website for at least three (3) years from the date that the information was most recently updated.

[return to Summary]

5. NON-COMPLIANCE CONSTITUTES MISCONDUCT

a. Non-compliance constitutes misconduct. In the event of non-compliance, the University may initiate actions under applicable collective and other agreements or University Policy.

b. Retrospective Review and Mitigation: Whenever the University identifies a SFI that was not disclosed in a timely fashion by an investigator or, for whatever reason, was not previously reviewed by the institution during an ongoing NIH-funded project (including but not limited to when the SFI was not reviewed in a timely fashion or reported by a subrecipient):

i. Step 1: the designated official shall, within sixty (60) days determine whether:

- the disclosures relate to NIH funding; and
  - an investigator’s SFI is related to NIH-funded research when the designated official reasonably determines that the SFI:
    o could be affected by the NIH-funded research; or
    o is an entity whose financial interest could be affected by the research.
The designated official may involve the investigator in the designated official's determination of whether a SFI is related to the NIH-funded research.
- each SFI is a FCOI.
  - a FCOI exists when the University, through its designated official, reasonably determines that the SFI could directly and significantly affect the design, conduct, or reporting of the NIH-funded research.

ii. Step 2: If the designated official determines that a FCOI exists, the designated official must implement, on at least an interim basis, a management plan that shall specify the actions that have been, and will be, taken to manage such FCOI going forward.

iii. Step 3: Within 120 days of the University’s determination of non-compliance, the University shall complete a retrospective review of the investigator’s activities and the NIH-funded project to determine whether any NIH-funded research, or portion thereof, conducted during the time period of the non-compliance, was biased in the design, conduct, or reporting of such research.

iv. Step 4: The University is required to document the retrospective review; such documentation shall include, but not necessarily be limited to, all of the following key elements:

- project number;
- project title;
- principal investigator or contact principal investigator if a multiple principal investigator model is used;
- name of the investigator with the FCOI;
- name of the entity with which the investigator has a FCOI;
- reason(s) for the retrospective review;
- detailed methodology used for the retrospective review (e.g., methodology of the review process, composition of the review panel, documents reviewed);
- findings of the review; and
- conclusions of the review.
v. Step 5: Based on the results of the retrospective review, if appropriate, the University shall update
the previously submitted FCOI report, specifying the actions that will be taken to manage the FCOI
going forward. If bias is found, the University is required to notify NIH promptly and submit a
mitigation report to NIH. The mitigation report must include, at a minimum, the key elements cited in
Step 4 above and a description of the impact of the bias on the project and the University’s plan of
action or actions taken to eliminate or mitigate the effect of the bias (including, but not limited to:
impact on the project; extent of harm done, including any qualitative and quantitative data to support
any actual or future harm; analysis of whether the project is salvageable).

vi. The University will, thereafter, submit FCOI reports annually as specified in Part 3 of this Procedure.

c. In any case in which the HHS determines that a NIH-funded project of clinical research whose purpose is to
evaluate the safety or effectiveness of a drug, medical device, or treatment has been designed, conducted,
or reported by an investigator with a FCOI that was not managed or reported by the University as required
by the regulations, the University must not only require the investigator involved to disclose the FCOI in
each public presentation of the results of the research, but also to request an addendum to previously
published presentations.

d. On the basis of its review of records or other information that may be available, NIH may decide that a
particular FCOI will bias the objectivity of the NIH-funded project to such an extent that further corrective
action is needed or that the University has not managed the FCOI in accordance with this procedure, the
NIH may determine that issuance of a Stop Work Order by the contracting officer or other enforcement
action is necessary until the matter is resolved.

[return to Summary]

DEFINITIONS

<table>
<thead>
<tr>
<th>Definition</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigator</td>
<td>The project director or principal investigator and any other person,</td>
</tr>
<tr>
<td></td>
<td>regardless of title or position, who is responsible for the design,</td>
</tr>
<tr>
<td></td>
<td>conduct, or reporting of research funded by the NIH or proposed for</td>
</tr>
<tr>
<td></td>
<td>such funding, which may include, for example, collaborators or consultants.</td>
</tr>
<tr>
<td></td>
<td>Investigator also includes senior/key personnel identified as such by the</td>
</tr>
<tr>
<td></td>
<td>University in the grant application, progress report, or any other report</td>
</tr>
<tr>
<td></td>
<td>submitted to the NIH by the University under this Procedure.</td>
</tr>
<tr>
<td>NIH</td>
<td>The National Institutes of Health (NIH) and other US Public Health Service</td>
</tr>
<tr>
<td></td>
<td>(PHS) funding sources, within the Department of Health and Human Services</td>
</tr>
<tr>
<td></td>
<td>(HHS), and any other research funding source which has adopted the HHS Final</td>
</tr>
<tr>
<td></td>
<td>Rule at 42 CFR Part 50 Subpart F and 45 CFR Part 94, “Responsibility of</td>
</tr>
<tr>
<td></td>
<td>Applicants for Promoting Objectivity in Research for which PHS Funding is</td>
</tr>
<tr>
<td></td>
<td>Sought and Responsible Prospective Contractors,” respectively. Other funding</td>
</tr>
<tr>
<td></td>
<td>sources which have adopted the aforementioned HHS Final Rule include those</td>
</tr>
<tr>
<td></td>
<td>listed by the US Federal Demonstration Partnership. Reporting requirements</td>
</tr>
<tr>
<td></td>
<td>under the Final Rule are administered by the National Institutes of Health.</td>
</tr>
<tr>
<td>Significant Financial Interest (SFI)</td>
<td>(1) A financial interest consisting of one or more of the following</td>
</tr>
<tr>
<td></td>
<td>interests of the investigator (and those of the investigator’s spouse and</td>
</tr>
<tr>
<td></td>
<td>dependent children) that reasonably appears to be related to the</td>
</tr>
<tr>
<td></td>
<td>investigator’s institutional responsibilities:</td>
</tr>
</tbody>
</table>
i. With regard to any publicly traded entity, a significant financial interest exists if the value of any remuneration received from the entity in the twelve months preceding the disclosure and the value of any equity interest in the entity as of the date of disclosure, when aggregated, exceeds $5,000. For purposes of this definition, remuneration includes salary and any payment for services not otherwise identified as salary (e.g., consulting fees, honoraria, paid authorship); equity interest includes any stock, stock option, or other ownership interest, as determined through reference to public prices or other reasonable measures of fair market value;

ii. With regard to any non-publicly traded entity, a significant financial interest exists if the value of any remuneration received from the entity in the twelve months preceding the disclosure, when aggregated, exceeds $5,000, or when the investigator (or the investigator’s spouse or dependent children) holds any equity interest (e.g., stock, stock option, or other ownership interest); or

iii. Intellectual property rights and interests (e.g., patents regardless of filing status, copyrights), upon receipt of income regarding those rights and interests in excess of $5,000 per year per entity (payor).

(2) Investigators also must disclose the occurrence of any reimbursed or sponsored travel (i.e., that which is paid on behalf of the investigator and not reimbursed to the investigator so that the exact monetary value may not be readily available), related to their institutional responsibilities when the annual aggregated amount paid to the specific investigator, exceeds $5,000 per entity; provided, however, that this disclosure requirement does not apply to travel that is reimbursed or sponsored by an US federal, state, or local government agency, an US institution of higher education, an US academic teaching hospital, an US medical center, or an US research institute that is affiliated with an US institution of higher education. This disclosure will include, at a minimum:

i. the purpose of the trip,

ii. the identity of the sponsor/organizer,

iii. the destination, and

iv. the duration.

The institutional official(s) will determine if further information is needed, including a determination or disclosure of monetary value, in order to determine whether the travel constitutes a FCOI with the NIH-funded research.

(3) If an investigator receives more than $5,000 per year from one entity in total payments for multiple SFIs (as defined in (1) and (2), above), then the details of each such SFI must be disclosed.

(4) Exclusions: The term significant financial interest does not include the following types of financial interests:

i. salary, royalties, or other remuneration paid by the University to the investigator if the investigator is currently employed or otherwise appointed by the University, including intellectual property rights assigned to the University and agreements to share in royalties related to such rights;
ii. income from investment vehicles, such as mutual funds and retirement accounts, as long as the investigator does not directly control the investment decisions made in these vehicles;

iii. income from seminars, lectures, or teaching engagements sponsored by an US federal, state, or local government agency, an US institution of higher education, an US academic teaching hospital, an US medical center, or an US research institute that is affiliated with an US institution of higher education; similar income from non-US equivalents of these entities where the annual aggregated amount paid to the specific investigator does not exceed $5,000 per entity; or

iv. income from service on advisory committees or review panels for an US federal, state, or local government agency, an US institution of higher education, an US academic teaching hospital, an US medical center, or an US research institute that is affiliated with an US institution of higher education; similar income from non-US equivalents of these entities where the annual aggregated amount paid to the specific investigator does not exceed $5,000 per entity.

<table>
<thead>
<tr>
<th>Designated Official</th>
<th>The individual appointed to this position by the University.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Institutional Responsibilities</td>
<td>Includes duties such as:</td>
</tr>
<tr>
<td>i.</td>
<td>participation in teaching programs, including classroom teaching, supervision of graduate students and personal interactions with and advising students;</td>
</tr>
<tr>
<td>ii.</td>
<td>participation in research (defined as including the preparation or performance of creative works and reflective inquiry) and the dissemination of the results of research by means appropriate to the discipline;</td>
</tr>
<tr>
<td>iii.</td>
<td>provision of service to the discipline of the staff member; participation in the governance of the University, the Faculty and the Department; and dissemination of knowledge to the general public by making available the staff member’s expertise and knowledge of the discipline all of which shall be carried out according to the standards of professional conduct expected of a staff member;</td>
</tr>
<tr>
<td>iv.</td>
<td>clinical service, if identified in the staff member’s job description; and</td>
</tr>
<tr>
<td>v.</td>
<td>any other responsibility outlined in the staff member’s job description, employment agreement or appointment letter with the University, in a post-doctoral fellow’s appointment letter with the University, in policies applicable to the post-doctoral fellows, or as identified in the University Calendar as a responsibility of a student to the University (as applicable).</td>
</tr>
</tbody>
</table>

| Financial Conflict of Interest (FCOI) | A SFI that could directly and significantly affect the design, conduct, or reporting of NIH-funded research. |
| Disclose | An investigator’s disclosure of SFIs to the University. |
| Financial Interest | Anything of monetary value, whether or not the value is readily ascertainable. |
Manage

Taking action to address a FCOI, which can include reducing or eliminating the FCOI, to ensure, to the extent possible, that the design, conduct, and reporting of research will be free from bias.

FORMS

Disclosure and Consent Form for Significant Financial Interests of Investigator
Disclosure and Consent Form for Significant Financial Interests of Spouse of Investigator
Disclosure and Consent Form for Significant Financial Interests of Dependent Child of Investigator
Informed Consent by Third Parties for Disclosure of Personal Information Form

RELATED LINKS

Department of Health and Human Services: 42 CFR Part 50 and 45 CFR Part 94 (United States Government)
United States Federal Demonstration Partnership